The Tianjin, China-based company, which was the first to move a vaccine into Phase II development, also became the first to published peer-reviewed data, from its Phase I study. Moderna released preliminary data this week, but it was seen as too early for interpreting its vaccine's efficacy.
J&J will work under an existing partnership with the department to develop a vaccine against COVID-19, while Moderna said it had produced the first batch of its own vaccine. Attendees at a recent biotech conference expressed concerns about the outbreak's impact on drug manufacturing.
Incorporating aquatic therapy can enhance patient outcomes and shorten recovery times for health care professionals. In the Chicago suburbs, the demand for such programs is rising.
A greater willingness to embrace new technologies has made it easier to develop vaccines against the 2019-nCoV virus, while newer drugs have also shown signs of efficacy, experts said. More than 17,000 were confirmed infected worldwide as of Monday, the WHO reported.
In an interview on CNBC's "Squawk Box," Paul Stoffels, the drugmaker's chief scientific officer, said the company had started working on a vaccine two weeks ago, but it could take a year to reach the market.